Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.

Autor: van Rijssen TJ; Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands., van Dijk EHC; Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands., Scholz P; Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany., Breukink MB; Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands., Dijkman G; Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands., Peters PJH; Department of Ophthalmology, Bergman Clinics B.V., Velp, The Netherlands., Tsonaka R; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands., Keunen JEE; Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands., MacLaren RE; Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust & NIHR Oxford Biomedical Research Centre, Oxford, UK., Hoyng CB; Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands., Downes SM; Nuffield Laboratory of Ophthalmology, University of Oxford and Oxford Eye Hospital, John Radcliffe Hospital, Oxford, UK., Fauser S; Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany.; F. Hoffmann-La Roche, Basel, Switzerland., Boon CJF; Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.; Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Jazyk: angličtina
Zdroj: Acta ophthalmologica [Acta Ophthalmol] 2021 Nov; Vol. 99 (7), pp. 805-811. Date of Electronic Publication: 2021 Feb 10.
DOI: 10.1111/aos.14775
Abstrakt: Purpose: To describe the treatment outcomes and recurrence risk of chronic central serous chorioretinopathy (cCSC) in patients who had complete resolution of subretinal fluid (SRF) after either primary half-dose photodynamic therapy (PDT) or high-density subthreshold micropulse laser (HSML) in the PLACE trial.
Methods: This multicentre prospective follow-up study evaluated cCSC patients at 1 year after completion of the PLACE trial. Outcomes included: complete resolution of SRF on OCT, best-corrected visual acuity (BCVA) in Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, retinal sensitivity on microperimetry and a visual function questionnaire (NEI-VFQ25).
Results: Twenty-nine out of 37 patients who received half-dose PDT and 15 out of 17 patients who received HSML could be evaluated at final visit. At final visit, 93% of the patients treated with half-dose PDT had complete resolution of SRF, compared with 53% of HSML-treated patients (p = 0.006). At final visit, the mean estimate increase in the PDT group compared with the HSML group was + 2.1 ETDRS letters, +0.15 dB for the retinal sensitivity and + 5.1 NEI-VFQ25 points (p = 0.103, p = 0.784 and p = 0.071, respectively). The mean estimated central retinal thickness in the half-dose PDT group was -7.0 µm compared with the HSML group (p = 0.566). The mean estimated subfoveal choroidal thickness in the half-dose PDT group was -16.6 µm compared with the HSML group (p = 0.359).
Conclusion: At 20 months after treatment, cCSC patients successfully treated with half-dose PDT are less likely to have recurrences of SRF compared with those successfully treated with HSML. However, functional outcomes did not differ.
(© 2021 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje